EMA to revoke PIP oncology waivers, says more cancer trials needed in children
This article was originally published in Scrip
Executive Summary
As a result of concerns that pharmaceutical companies are not conducting enough clinical trials in children, the European Medicines Agency's pediatrics committee (PDCO) is planning to revoke class waivers for paediatric investigation plans in some conditions on the grounds that the waivers are preventing the agency from requesting studies in children, especially in the field of oncology. The move would not affect drugs already on the market, unless they were submitted for review in additional indications.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.
EMA To Get The Ball Rolling On Making CTIS Global
The European Medicines Agency wants to further improve the visibility of data in the Clinical Trials Information System by establishing it as a World Health Organization primary registry.